Identification of two cancer-associated fibroblast markers revealing stromal heterogeneity in sustaining cancer progression and chemoresistance

Intra-tumor cellular heterogeneity is a key player of tumor aggressiveness and resistance to therapies. Genetic diversity in tumor cells enables, under selective pressures (e.g., during the metastatic process or under therapies), the rise of certain subclones proficient with survival and metastatic advantages (1).